Alphamab Oncology to launch HK$30m share buyback program

Alphamab Oncology's board of directors resolved on November 7, 2025, to repurchase up to HK$30m worth of its ordinary shares in the open market. This buyback will be executed under the general mandate approved by shareholders on June 12, 2025. The company intends to finance the repurchases using its existing available cash and will adhere to regulatory guidelines, ensuring the repurchase price does not exceed 5% or more than the average closing price over the five preceding trading days.

The board believes the current trading price does not accurately reflect Alphamab Oncology's intrinsic value, and that the share repurchases will bolster confidence in its business outlook and prospects. Decisions regarding whether repurchased shares will be canceled or held as treasury shares will depend on market conditions and the group's capital management needs. The company also confirmed that as of the announcement date, it has already repurchased 1,681,000 shares under a previous mandate, holding them as treasury shares.

Shareholders and potential investors are cautioned that the implementation of the on-market share repurchase is subject to market conditions and the discretion of the board, with no assurance regarding timing, quantity, or price of repurchases.